Pfizer And Shionogi Form Vanguard In New Subscription Assault On Antibiotic Resistance

Deals Signed With UK’s NHS Pilot Scheme

Two antibiotics from Pfizer and Shionogi are to be rolled out by the UK’s NHS in a pioneering subscription deal that hopes to encourage antibiotic R&D by delinking payment from volume of use.  

• Source: Shutterstock

A scheme to solve the seemingly intractable problem of creating a viable market for companies developing novel antimicrobials has got underway in the UK, with antibiotics from Pfizer Inc. and Shionogi & Co. Ltd. leading the charge.

The two firms have signed agreements with NHS England for an innovative payment model for reimbursement of their respective antibiotics,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Glenmark Fortifying Branded Play, Shifts Focus To High Margin Products

 

Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.

China-Originated Assets Lead Global GLP-1 Deals

 
• By 

The total deal value of GLP-1-associated assets globally this year is already double that of the previous two years combined, with China-originated assets accounting for a substantial majority.

Boehringer Expands Eyecare Horizons With Palatin Collaboration

 

The German company already had four eye disease candidates in Phase II development and sees promise in Palatin’s novel melanocortin receptor modulators.

Skyhawk Flies High With Another Big Pharma, Getting Up To $2bn In Merck KGaA Deal

 
• By 

Deal Snapshot: Skyhawk raised its first seed funding in 2018 and has funded its operations primarily through partnering fees to date, including its latest agreement with Merck KGaA.

More from Business

Discontinuations For Viking’s Oral Obesity Drug VK2735 Scare Investors

 
• By 

Analysts lauded the 13-week weight-reduction rates Viking’s oral dual GLP-1/GIP agonist showed in Phase II, but the firm’s stock tumbled 42% due to high discontinuation rates.

Boehringer Expands Eyecare Horizons With Palatin Collaboration

 

The German company already had four eye disease candidates in Phase II development and sees promise in Palatin’s novel melanocortin receptor modulators.

Egetis Eyes Swift US Submission For Emcitate

 
• By 

The Sweden-based firm is set for talks with the FDA on the regulatory path for its MCT8 deficiency candidate.